Member Info for woodyjohn40

Because of the non existent news flow and posts on here, i am losing all faith in Icon, I’ve messaged the company and registrars but had no response, so I am writing off my £42k invested, yes I know I’m an idiot but I will not starve.
What is more annoying is that I could have invested this is a needy charity or two, they would have made better use of my hard earned money. I hope the both BOD’s and all involved in this disgraceful exhibition of how (not) to treat shareholders are pleased with them selves, i hope they can sleep well at night . GLA and good night.

What news do people think will come from the general meeting, or is the meeting pointless?

Oxford, U.K. -26 January 2022: Sensyne Health plc (LSE:SENS), the UK clinical AI company, announces it has successfully completed the financing announced on 14 January 2022.

The financing comprises up to £11.35 million (comprising a first tranche of £6.35 million and an additional tranche of £5 million by mutual consent) and will fund the business through the ongoing Formal Sale Process. Lord Drayson has confirmed his commitment to the Company's mission and its unique ethical business model for the use of anonymised patient data in medical research in partnership with the NHS and health systems world-wide. He has proposed and the Company has agreed that he will reduce his base salary to £1 per annum while the Loan Notes are outstanding and he has committed to vote for any bid for the Company that results from the Formal Sale Process that is consistent with the Company's mission and maximises value for shareholders or is recommended by the independent Directors

Sierra, Oncology opens %50 up on the NASDAQ
Let’s hope it helps here.

I think I’m correct in saying thi share is up over %84 in the USA. (Apologies if already posted)

I agree %100 but the wait is driving me crazy. I have emailed icon pleading for an update, but as yet no reply, Grrrrr

I think when The trading is open ,it will change to Zero value (sorry if I am correct).

Looks good, woohoo

Lois good, I can’t wait for the relishing. Woohoo

As we now have an idea of the price for tester box and test, what would be a ball park figure for an outright sale of Paraytec. ???

As we now have an idea of the price for tester box and test, what would be a ball park figure for an outright sale of Paraytec. ???

End of RNS Update.

Sepsis Test

Paraytec has commenced the development of a blood-based test for the identification of microbial pathogens which are causative agents in the development and emergence of sepsis. The test will be based on the existing CX300 platform.

In the first instance, the sepsis test will focus on discriminating between the presence of E. coli, Pseudomonas and Staphylococcus. These combined species account for over 50% of all sepsis cases in the UK. The test will be developed in a similar way to the COVID-19 test, in this case rapidly and specifically targeting these bacterial species and labelling them with one of a number of fluorescent dyes.

The CX300 platform will also be developed further to discriminate between the various wavelengths of light emitted from distinct fluorescent dyes, and to accommodate the volumes of fluid involved in a standard blood test, typically 5 -10 millilitres.

Bladder Cancer Test

In parallel with the above work, a screening process will be used to identify antibody molecules that discriminate between normal and cancerous bladder cells for the bladder cancer test. The team will identify a panel of antibodies that recognise bladder cancer cells, while avoiding the need to identify specific bladder cancer biomarkers.

As with the test for sepsis, the bladder cancer test utilises Paraytec's existing CX300 platform, which will be adapted for screening the typical volumes of urine that would be collected from patients in a clinical setting.

Wed, 8th Dec 2021 07:00

RNS Number : 9029U
Braveheart Investment Group plc
08 December 2021

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

8 December 2021

Braveheart Investment Group plc

("Braveheart" or the "Group")

Operational update on Paraytec

Braveheart Investment Group plc (AIM: BRH), is pleased to provide the following update on Paraytec, a company within the Group's investment portfolio.



COVID-19 Test



As reported in the Half-Yearly Report on 15 November 2021, the Paraytec team has engaged Sagentia International, to assist with the development of our test cartridge.



The design, production and supply of a competitively priced test cartridge is critical to the realisation of the full commercial potential of the Paraytec test. Paraytec are very pleased that design analysis suggests the production cost will be less than £2 per cartridge.



Similarly, the projected manufacturing cost of the CX300 instrument, required to analyse the patient specimen and provide the test result, is likely to be in the region of £1,500 per instrument. This relatively low cost means that CX300 instruments could be offered for a nominal charge with a minimum initial purchase of cartridges, a marketing and business model successfully pursued by printer manufacturers, razor blade manufacturers and others.



As previously indicated, the Paraytec team will commence a prospective clinical study early in the new year, followed by a longitudinal study. Discussions with potential commercial partners and acquirers are now continuing in some depth, with some prospective counter parties having completed a third round of such meetings. The Braveheart board continues to assess what is likely to result in the best outcome for shareholders, whether it is from the potential sale, partnership or retention and full development of the technology.



Omicron: The Paraytec and Sheffield University team are confident that the test will work with Omicron and other variants, as Paraytec's test to detect the COVID-19 virus uses antibodies to attach a specific fluorescent dye to the surface of each virus particle. The antibodies used in the test have been selected to recognise the viral Spike protein. While mutations in the Omicron variant give rise to over 30 amino acid changes in the Spike protein, all of these occur in a region of the protein which is distinct from that recognised by the antibodies selected for the Paraytec test.



Sepsis Test

Paraytec has commenced the development of a blood-based test for the identification of microbial pathogens which are causative agents in the development and emergence of sepsis. The test will be based on

This only amounts to a small fraction of the trades that vanished, spooky hey.

Thank you SM888 and JR.

They were all definitely Buys.

On level two, at approximately 15:41 I saw at least five trades between £100,000 and £150,000 and one trade out £2 million, I looked again five minutes later and they had vanished, what is going on ?

We should all share this video on all social media platforms, i will immediately,

Tuesday, November 2021, there are 2 Tuesdays left in November?????

I have mailed the FCA ,expressing the shareholders disgust and the importance of an investigation into both Icon and the JA’s
unprofessional and dishonest way they have been conducting this whole delisting event, also advised them that I will be speaking to my local MP Angela Raynor if no satisfactory reply is received.